Unfazed by Dengvaxia difficulties, Takeda presses on with TAK-003

Japan’s Takeda Pharmaceutical (TYO: 4502) has announced positive Phase III data from a trial of its dengue vaccine candidate TAK-003.

Results from the TIDES trial, which enrolled over 20,000 healthy children and adolescents in dengue-endemic areas, show the study met its primary efficacy endpoint, and that TAK-003 was efficacious in preventing dengue fever caused by any of the four serotypes of the virus.

The firm said that, while “review of the extensive data set is ongoing,” TAK-003 was well tolerated with no significant safety concerns to date. The trial is testing the impact of two doses of TAK-003, in both dengue exposed and naïve individuals.